<PAGE> 1
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
SCHEDULE 13G
UNDER THE SECURITIES EXCHANGE ACT OF 1934
(AMENDMENT NO. 1 )*
BOSTON BIOMEDICA, INC.
- --------------------------------------------------------------------------------
(Name of Issuer)
COMMON STOCK, $.01 PAR VALUE PER SHARE
- --------------------------------------------------------------------------------
(Title of Class of Securities)
100560101
-------------------
(CUSIP Number)
December 31, 1999
- --------------------------------------------------------------------------------
(Date of Event which Requires Filing of this Statement)
Check the appropriate box to designate the rule pursuant to which this Schedule
is filed:
| | Rule 13d-1(b)
| | Rule 13d-1(c) (Amendment filed pursuant to Rule 13d-2(b))
|X| Rule 13d-1(d)
*The remainder of this cover page shall be filled out for a reporting person's
initial filing on this form with respect to the subject class of securities, and
for any subsequent amendment containing information which would alter the
disclosures provided in a prior cover page.
The information required in the remainder of this cover page shall not be deemed
to be "filed" for the purpose of Section 18 of the Securities Exchange Act of
1934 ("Act") or otherwise subject to the liabilities of that section of the Act
but shall be subject to all other provisions of the Act (however, see the
Notes).
Page 1 of 7 pages
<PAGE> 2
13G
CUSIP No. 100560101 Page 2 of 7 Pages
------------ --- ---
- --------------------------------------------------------------------------------
1 NAME OF REPORTING PERSON
I.R.S. IDENTIFICATION NUMBER OF ABOVE PERSON (Entities only)
Irwin J. Gruverman
- --------------------------------------------------------------------------------
2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (a) [ ]
(b) [ ]
- --------------------------------------------------------------------------------
3 SEC USE ONLY
- --------------------------------------------------------------------------------
4 CITIZENSHIP OR PLACE OF ORGANIZATION
United States of America
- --------------------------------------------------------------------------------
5 SOLE VOTING POWER
105,371 shares (consisting of (a) 6,667 shares of
Common Stock, (b) 10,000 options to purchase common
stock, (c) 1,037 warrants to purchase common stock,
(d) 85,593 shares of common stock owned by G&G
Diagnostics, L.P., of which Mr. Gruverman is General
NUMBER OF Partner, and (e) 2,074 Warrants to purchase common
SHARES owned by G&G Diagnostics, L.P.).
BENEFICIALLY ------------------------------------------------------------
OWNED BY 6 SHARED VOTING POWER
EACH
REPORTING 0
PERSON WITH
------------------------------------------------------------
7 SOLE DISPOSITIVE POWER
105,371 shares (consisting of (a) 6,667 shares of
Common Stock, (b) 10,000 options to purchase common
stock, (c) 1,037 warrants to purchase common stock,
(d) 85,593 shares of common stock owned by G&G
Diagnostics, L.P., of which Mr. Gruverman is General
Partner, and (e) 2,074 Warrants to purchase common
stock owned by G&G Diagnostics, L.P.).
------------------------------------------------------------
8 SHARED DISPOSITIVE POWER
0
- --------------------------------------------------------------------------------
9 AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
105,371 shares (consisting of (a) 6,667 shares of Common Stock, (b)
10,000 options to purchase common stock, (c) 1,037 warrants to purchase
common stock, (d) 85,593 shares of common stock owned by G&G
Diagnostics, L.P., of which Mr. Gruverman is General Partner, and
(e) 2,074 Warrants to purchase common owned by G&G Diagnostics, L.P.).
- --------------------------------------------------------------------------------
10 CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES
[ ]
- --------------------------------------------------------------------------------
11 PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)
2.2 %
- --------------------------------------------------------------------------------
12 TYPE OF REPORTING PERSON
IN
- --------------------------------------------------------------------------------
Page 2 of 7 pages
<PAGE> 3
Item 1(a). NAME OF ISSUER
Boston Biomedica, Inc.
Item 1(b). ADDRESS OF ISSUER'S PRINCIPAL OFFICE
375 West Street
West Bridgewater, Massachusetts 02379
Item 2(a). NAME OF PERSON FILING
Irwin J. Gruverman
Item 2(b). ADDRESS OF PRINCIPAL BUSINESS OFFICE, OR IF
NONE, RESIDENCE
30 Ossipee Road
Newton, Massachusetts 02164
Item 2(c). CITIZENSHIP
United States of America
Item 2(d). TITLE OF CLASS OF SECURITIES
Common Stock, par value $.01 per share
Item 2(e). CUSIP NUMBER
100560101
Item 3. If this statement is filed pursuant to Rules
13d-1(b), or 13d-2(b) or (c), check whether
the person filing is a:
(a)[ ] Broker or dealer registered under Section 15 of
the Exchange Act
(b)[ ] Bank as defined in Section 3(a)(6) of the
Exchange Act.
(c)[ ] Insurance company as defined in
Section 3(a)(19) of the Exchange Act.
(d)[ ] Investment company registered under Section 8
of the Investment Company Act.
(e)[ ] Investment adviser in accordance with
Rule 13d-1(b)(1)(ii)(E).
(f)[ ] Employee benefit plan, or endowment fund in
accordance with Rule 13d-1(b)(1)(ii)(F).
(g)[ ] Parent holding company or control person, in
accordance with Rule 13d-1(b)(1)(ii)(G).
(h)[ ] A savings association as defined in Section
3(b) of the Federal Deposit Insurance Act.
(i)[ ] A church plan that is excluded from the
definition of an investment company under
Section 3(c)(14) of the Investment Company Act.
(j)[ ] Group, in accordance with
Rule 13d-1(b)(1)(ii)(J).
Page 3 of 7 pages
<PAGE> 4
Item 4. OWNERSHIP
Provide the following information regarding
the aggregate number and percentage of the
class of the securities of the issuer
identified in Item 1.
(a) Amount Beneficially Owned:
105,371 shares (consisting of (a) 6,667
shares of Common Stock, (b) 10,000 options
to purchase common stock, (c) 1,037 warrants
to purchase common stock, (d) 85,593 shares
of common stock owned by G&G Diagnostics,
L.P., of which Mr. Gruverman is General
Partner, and (e) 2,074 Warrants to purchase
common owned by G&G Diagnostics, L.P.).
(b) Percent of Class:
2.2 %
(c) Number of shares as to which such
persons has:
(i) sole power to vote or to direct
the vote:
105,371 shares (consisting of (a) 6,667
shares of Common Stock, (b) 10,000 options
to purchase common stock, (c) 1,037 warrants
to purchase common stock, (d) 85,593 shares
of common stock owned by G&G Diagnostics,
L.P., of which Mr. Gruverman is General
Partner, and (e) 2,074 Warrants to purchase
common owned by G&G Diagnostics, L.P.).
(ii) shared power to vote or to direct
the vote:
-0-
(iii) sole power to dispose or to
direct the disposition of:
105,371 shares (consisting of (a) 6,667
shares of Common Stock, (b) 10,000 options
to purchase common stock, (c) 1,037 warrants
to purchase common stock, (d) 85,593 shares
of common stock owned by G&G Diagnostics,
L.P., of which Mr. Gruverman is General
Partner, and (e) 2,074 Warrants to purchase
common owned by G&G Diagnostics, L.P.).
(iv) shared power to dispose or to
direct the disposition of:
-0-
Page 4 of 7 pages
<PAGE> 5
Item 5. OWNERSHIP OF FIVE PERCENT OR LESS OF A
CLASS.
If this statement is being filed to report
the fact that as of the date hereof the
reporting person has ceased to be the
beneficial owner of more than five percent
of the class of securities, check the
following [X].
Item 6. OWNERSHIP OF MORE THAN FIVE PERCENT ON
BEHALF OF ANOTHER PERSON.
If any other person is known to have the
right to receive or the power to direct the
receipt of dividends from, or the proceeds
from the sale of, such securities, a
statement to that effect should be included
in response to this item and, if such
interest relates to more than five percent
of the class, such person should be
identified. A listing of the shareholders of
an investment company registered under the
Investment Company Act of 1940 or the
beneficiaries of employee benefit plan,
pension fund or endowment fund is not
required.
Inapplicable
Item 7. IDENTIFICATION AND CLASSIFICATION OF THE
SUBSIDIARY WHICH ACQUIRED THE SECURITY BEING
REPORTED ON BY THE PARENT HOLDING COMPANY.
If a parent holding company has filed this
schedule, pursuant to Rule 13d-1(b)(ii)(G),
so indicate under Item 3(g) and attach an
exhibit stating the identity and Item 3
classification of the relevant subsidiary.
If a parent holding company has filed this
schedule pursuant to Rule 13d-1(c), attach
an exhibit stating the identification of the
relevant subsidiary.
Inapplicable
Item 8. IDENTIFICATION AND CLASSIFICATION OF MEMBERS
OF THE GROUP.
If a group has filed this schedule, pursuant
to Rule 13d-1(b)(1)(ii)(J), so indicate
under Item 3(h) and attach an exhibit
stating the identity and Item 3
classification of each member of the group.
If a group has filed this schedule pursuant
to Rule 13d-1(d), attach an exhibit stating
the identity of each member of the group.
Inapplicable
Page 5 of 7 pages
<PAGE> 6
Item 9. NOTICE OF DISSOLUTION OF GROUP.
Notice of dissolution of a group may be
furnished as an exhibit stating the date of
the dissolution and that all further filings
with respect to transactions in the security
reported on will be filed, if required, by
the members of the group, in their
individual capacity. (See Item 5.)
Inapplicable
Item 10. CERTIFICATION.
By signing below I certify that, to the best
of my knowledge and belief, the securities
referred to above were not acquired and are
not held for the purpose of or with the
effect of changing or influencing the
control of the issuer of the securities and
were not acquired and are not held in
connection with or as a participant in any
transaction having such purposes or effect.
[REMAINDER OF PAGE INTENTIONALLY LEFT BLANK]
Page 6 of 7 pages
<PAGE> 7
SIGNATURE
After reasonable inquiry and to the best of my knowledge and belief, I certify
that the information set forth in this statement is true, complete and correct.
Date: March 1, 2000
-------------------------
Signature: /s/ Irwin J. Gruverman
-------------------------
Name/Title: Irwin J. Gruverman
--------------------------
Page 7 of 7 pages
